BGB-290-AU-102: This phase I/II trial is evaluating the safety and recommended dose of a combined targeted therapy (BGB-A425 and Tislelizumab) in patients with advanced solid cancersPhase 1-2 Study Investigating Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Anti-TIM-3 Monoclonal Antibody BGB-A425 in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors

Exclusion

• NSCLC patients with known EGFR mutation, BRAF mutation, ALK fusion, or ROS1 fusion
• Active leptomeningeal disease or uncontrolled, untreated brain metastasis.
• Active autoimmune diseases or history of autoimmune diseases that may relapse.
• Interstitial lung disease, noninfectious pneumonitis or uncontrolled lung diseases
• Uncontrolled diabetes or significant cardiac issues
• Infections requiring systemic antibacterial, antifungal, or antiviral therapy
• History of severe hypersensitivity reactions to other monoclonal antibodies
• History of HIV infection or untreated chronic hepatitis B or chronic hepatitis B virus carriers
• Major surgical procedure within 28 days before study drug administration
• Chemotherapy, radiotherapy, immunotherapy or any investigational therapies within 28 days (PH 2 Safety Lead-In) or 14 days (PH 2 Dose Expansion) or 5 half-lives of (whichever is shorter) of first administration of study drug(s).
• With infections (including tuberculosis infection, etc) requiring systemic antibacterial, antifungal, or antiviral therapy ≤ 14 days prior to the first dose of study drug(s), or a requirement for chronic prophylactic treatment with antibiotics.
• Concurrent participation in another therapeutic clinical trial
• Received prior therapies targeting TIM-3and/or LAG3